Cellular response and molecular mechanism of antitumor activity by leinamycin in MiaPaCa human pancreatic cancer cells.

Abstract:

:Previous in vitro biochemical studies have revealed that the antitumor drug leinamycin causes oxidative DNA damage and DNA alkylation. However, it is still not clear whether the same mechanism(s) of action operate in cultured human tumor cells. Here, we evaluated the effects of leinamycin in the human pancreatic carcinoma cell line MiaPaCa. Leinamycin was highly toxic to MiaPaCa cells in vitro, with an IC50 value of 50 nM, and extensive DNA fragmentation was observed in leinamycin-treated MiaPaCa cells. Flow cytometric experiments showed that leinamycin was able to disrupt normal cell cycle progression, resulting in an initial arrest of the cells in S phase. With increased time or at higher concentrations of leinamycin, the population of cells in the sub-G1 phase gradually increased, indicative of apoptotic cell death due to DNA damage. Mammalian Chk2, but not Chk1 kinase, was found to be activated in MiaPaCa cells treated with leinamycin, indicating that cellular responses to leinamycin could be attributed to DNA strand break formation rather than DNA adduct formation. Like other DNA-damaging anticancer drugs, the downregulation of telomerase activity was also observed in MiaPaCa cells at cytotoxic concentrations. However, leinamycin failed to induce DNA ligase I expression in MiaPaCa cells, unlike other DNA-damaging agents, which are known to inhibit DNA replication by arresting DNA replication forks. Taken together, the results from our study indicate that the DNA strand breakage caused by the oxidative DNA-damaging property of leinamycin is directly related to the cellular responses of this drug in MiaPaCa cells over the DNA alkylation property in a dose-responsive manner.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Bassett S,Urrabaz R,Sun D

doi

10.1097/01.cad.0000136886.72917.6f

subject

Has Abstract

pub_date

2004-08-01 00:00:00

pages

689-96

issue

7

eissn

0959-4973

issn

1473-5741

pii

00001813-200408000-00005

journal_volume

15

pub_type

杂志文章
  • The impact of taxanes on the management of genitourinary cancers.

    abstract::Taxanes have had a profound impact on the management of genitourinary tumors. In the perioperative and metastatic setting in bladder cancer, taxanes such as paclitaxel have an established role in combination chemotherapy strategies to improve survival. In metastatic prostate cancer, docetaxel was the only treatment, u...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000088

    authors: Balar AV

    更新日期:2014-05-01 00:00:00

  • Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer.

    abstract::The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bladder at stage Ta or T1 that was proven refractory to or in relapse af...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199104000-00005

    authors: Sharifi R,Lee M,Clayton M,Lamb D,Siami P,Strub M,Albert D,Sarosdy M

    更新日期:1991-04-01 00:00:00

  • Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.

    abstract::Cancer invasion and metastasis are highly complex processes and a serine protease urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system has been postulated to play a central role in the mediation of cancer progression. Of note, malignant tumor urokinase-type plasminogen activator an...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/01.cad.0000231483.09439.3a

    authors: Nozaki S,Endo Y,Nakahara H,Yoshizawa K,Ohara T,Yamamoto E

    更新日期:2006-11-01 00:00:00

  • Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.

    abstract::Fibroblast growth factor-inducible 14 (Fn14) has been reported to play an oncogene role in many types of cancer. However, its biological functions in small-cell lung cancer (SCLC) remain unknown. The aim of this study is to investigate the roles of Fn14 in the cell growth and chemoresistance of SCLC and its possible m...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000153

    authors: Li X,Zhu W,Chen Z,Luo L,Huang J,Zhang F,Li M,Guo Y,Guo L

    更新日期:2014-11-01 00:00:00

  • Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.

    abstract::Hemolytic uremic syndrome (HUS) is a rare clinical and biological entity. HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens. Little information is available concerning the occurrence and outcome of this syndrome after administration of more recen...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199907000-00004

    authors: Gross M,Hiesse C,Kriaa F,Goldwasser F

    更新日期:1999-07-01 00:00:00

  • Pazopanib, a promising option for the treatment of aggressive fibromatosis.

    abstract::Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of agents are used. Tyrosine kinase inhibitors have recently been reported to show useful activity. We r...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000474

    authors: Szucs Z,Messiou C,Wong HH,Hatcher H,Miah A,Zaidi S,van der Graaf WT,Judson I,Jones RL,Benson C

    更新日期:2017-04-01 00:00:00

  • Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

    abstract::The cytotoxic activity of bendamustine hydrochloride was evaluated against human ovarian and breast carcinoma cell lines including cell lines resistant to cisplatin and doxorubicin in vitro. The relative degree of resistance to bendamustine hydrochloride was lower in all cell lines compared with cyclophosphamide, melp...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199606000-00007

    authors: Strumberg D,Harstrick A,Doll K,Hoffmann B,Seeber S

    更新日期:1996-06-01 00:00:00

  • In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.

    abstract::Individual response of disseminated cancer to chemotherapy is unpredictable. In vitro chemotherapy-induced apoptosis can be measured and might be a method to evaluate in vivo activity of tested drugs. In this report, tumor cells of a patient with signet cell carcinoma of the stomach and diffuse bone marrow infiltratio...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200501000-00013

    authors: Trojan J,Kim SZ,Engels K,Kriener S,Mitrou PS,Chow KU

    更新日期:2005-01-01 00:00:00

  • Tamoxifen as a potential treatment of glioma.

    abstract::Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit th...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199808000-00001

    authors: Mastronardi L,Puzzilli F,Ruggeri A

    更新日期:1998-08-01 00:00:00

  • Inhibition of NADPH oxidase protects against metastasis of human lung cancer by decreasing microRNA-21.

    abstract::The objective of this study was to detect the effect of NADPH oxidase (NOX) inhibition on metastasis of lung cancer. Primary human lung cancer cells were isolated from surgical tissues using the Cancer Cell Isolation Kit. Invasion was detected using the BD Biocoat Matrigel Invasion Chamber assay. Expressions of microR...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000198

    authors: Yan S,Liu G,Pei C,Chen W,Li P,Wang Q,Jin X,Zhu J,Wang M,Liu X

    更新日期:2015-04-01 00:00:00

  • Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.

    abstract::Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer. Pegylated liposomal doxorubicin (Caelyx) has been combined with this regimen in a phase I study exhibiting promising activity in patients with upper gastrointestinal tumors...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200504000-00010

    authors: Gnad-Vogt SU,Hofheinz RD,Saussele S,Kreil S,Willer A,Willeke F,Pilz L,Hehlmann R,Hochhaus A

    更新日期:2005-04-01 00:00:00

  • SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.

    abstract::Leucine-rich repeat containing G protein-coupled receptor 5 (Lgr5) is a colorectal cancer (CRC) stem cell marker. The role of Lgr5-expressing stem cells in resistance to chemotherapy is controversial. The notion that Lgr5-expressing cells are more chemotherapy resistant is supported by some data; other data do not sup...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000270

    authors: Planutis AK,Holcombe RF,Planoutene MV,Planoutis KS

    更新日期:2015-10-01 00:00:00

  • Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer.

    abstract::Patients with metastatic squamous cell cancer of the head and neck (SCCHN) have a poor prognosis, with most patients surviving less than a year. Immunotherapy (IO) is changing the natural history of the disease and programmed death-ligand 1 (PD-L1) inhibitors are showing notable improvements in survival with a more fa...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000706

    authors: Cabezas-Camarero S,Cabrera-Martín MN,Pérez-Segura P

    更新日期:2019-02-01 00:00:00

  • Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis.

    abstract::Prostaglandin E2 (PGE2) has been shown to play an important role in tumor development and progression. PGE2 mediates its biological activity by binding any one of four prostanoid receptors (EP1 through EP4). The present study was designed to determine the role of the EP2 receptor during the proliferation and apoptosis...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835a4dac

    authors: Hu S,Sun W,Wei W,Wang D,Jin J,Wu J,Chen J,Wu H,Wang Q

    更新日期:2013-02-01 00:00:00

  • The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, MDL 101,731.

    abstract::(E)-2'-deoxy-2'-(fluoromethylene) cytidine (MDL101,731) is a new deoxycytidine analog which shows potent antitumor activity against several human tumor models. We previously showed that MDL101,731 inhibited human ribonucleotide reductase (RNR) in HeLa S3 human cervical carcinoma cells. Recently, it has been reported t...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199808000-00011

    authors: Kanazawa J,Takahashi T,Akinaga S,Tamaoki T,Okabe M

    更新日期:1998-08-01 00:00:00

  • Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy O

    abstract::Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v. on day 1-3, cyclophosphamide (CTX) 600 mg/m2 i.v. on day 1 and mitoxantrone (DHAD) 12 mg/m2 i.v. on day 1. DHAD dose was progressiv...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-199703000-00006

    authors: Colucci G,Giotta F,Gebbia V,Riccardi F,Pezzella G,Durini E,Caruso M,Romito S,Gebbia N

    更新日期:1997-03-01 00:00:00

  • Inhibition of breast tumor growth in mice after treatment with ceramide analog 315.

    abstract::The aim of this study was to evaluate the anticancer and antitumor activities of ceramide analog 315 in nude mice. Nude mice (n=10) were injected bilaterally with 5×10 MDA-MB-231 cells on each side. Tumors were allowed to form for 2 weeks. The mice were then divided into two groups (n=5 in each group). The control gro...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000675

    authors: Ponnapakkam T,Saulsberry T,Hill T,Hill-Odom M,Goyal N,Anbalagan M,Liu J,Foroozesh M

    更新日期:2018-10-01 00:00:00

  • The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells.

    abstract::Apoptosis is important for normal development and removal of damaged cells. Evasion of apoptosis by cancer cells is one of the key characteristics of many tumor types. Thus, discovering agents that promote apoptosis in tumor cells could have great therapeutic value. Marine natural products have demonstrated great pote...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832ae55f

    authors: LaBarbera DV,Modzelewska K,Glazar AI,Gray PD,Kaur M,Liu T,Grossman D,Harper MK,Kuwada SK,Moghal N,Ireland CM

    更新日期:2009-07-01 00:00:00

  • Long-term results of paclitaxel in FIGO stage III ovarian carcinoma.

    abstract::The combination of platinum and paclitaxel is the standard treatment of advanced ovarian carcinoma; however, recent studies have questioned the actual role of the combination as compared to either of the two agents alone. We report an open-label, two-center, phase II study of upfront paclitaxel for patients with histo...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200306000-00004

    authors: Gallardo-Rincón D,Pérez-Landeros L,Oñate-Ocaña LF,Mohar A,Calderillo G,de la Garza J,Cabrera P,Sánchez B,Dueñas-Gonzalez A

    更新日期:2003-06-01 00:00:00

  • Nutritional support in head and neck cancer: how and why?

    abstract::To devise a meaningful nutritional therapy in cancer, a greater understanding of nutritional dimensions as well as of expectations of patients and disease impact is essential. We have shown that nutritional deterioration in patients with gastrointestinal and head and neck cancer was multifactorial and mainly determine...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e328345b4c5

    authors: Ravasco P

    更新日期:2011-08-01 00:00:00

  • MiR-29b suppresses proliferation and mobility by targeting SOX12 and DNMT3b in pancreatic cancer.

    abstract::Pancreatic cancer is one of the leading causes of solid carcinoma with the worst survival rate. The reasons for the worst survival rate include the lack of biomarkers for early detection, diagnosis at a late stage, and the limitation of the current therapy. Further study to investigate the underlying molecular mechani...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000719

    authors: Wang L,Wang Z,Huang L,Wu C,Zhang B

    更新日期:2019-03-01 00:00:00

  • Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study.

    abstract::Epidemiological and clinical studies suggesting a significant inverse relationship between intake of dietary selenium and overall cancer risk have led to initiation of a randomized, placebo-controlled, phase III clinical trial testing the safety and efficacy of selenized yeast as a chemopreventive agent for prostate c...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00001813-200309000-00003

    authors: Stratton MS,Reid ME,Schwartzberg G,Minter FE,Monroe BK,Alberts DS,Marshall JR,Ahmann FR

    更新日期:2003-09-01 00:00:00

  • Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.

    abstract::The aim of this study was to evaluate the effect of coadministration of acid-reducing agents on the pharmacokinetic exposure of orally administered epidermal growth factor receptor inhibitor erlotinib, a drug that displays pH-dependent solubility. Two studies were conducted, the first with the proton pump inhibitor om...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/CAD.0000000000000212

    authors: Kletzl H,Giraudon M,Ducray PS,Abt M,Hamilton M,Lum BL

    更新日期:2015-06-01 00:00:00

  • A clinical armamentarium of marine-derived anti-cancer compounds.

    abstract::The sea, covering 70% of the Earth's surface, offers a considerably broader spectrum of biological diversity than terra firma. Containing approximately 75% of all living organisms, the marine environment offers a rich source of natural products with potential therapeutic application. Marine organisms have evolved the ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Jimeno JM

    更新日期:2002-05-01 00:00:00

  • 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.

    abstract::1,4-Anthraquinone (AQ) was synthesized and shown to prevent L1210 leukemic cells from synthesizing macromolecules and growing in vitro. In contrast, its dihydroxy-9,10anthraquinone precursor, quinizarin, was inactive. The antitumor activity of AQ was compared to that of daunorubicin (DAU), which is structurally differ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200006000-00004

    authors: Perchellet EM,Magill MJ,Huang X,Dalke DM,Hua DH,Perchellet JP

    更新日期:2000-06-01 00:00:00

  • Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles.

    abstract::Docetaxel (DTX) is one of the most effective antineoplastic drugs. However, its current clinical administration, formulated in tween80, causes serious side effects. This study is focused on preparation and evaluation of poly(lactide-co-glycolide) nanoparticles (NPs) containing DTX to remove tween80. Drug encapsulation...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328331f934

    authors: Esmaeili F,Dinarvand R,Ghahremani MH,Ostad SN,Esmaily H,Atyabi F

    更新日期:2010-01-01 00:00:00

  • Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange.

    abstract::To investigate whether mammalian DNA topoisomerase II is directly involved in recombination events, the effects of ICRF-193, a specific catalytic inhibitor on sister chromatid exchange (SCE), were examined in MR-6 cells. ICRF-193 only slightly elevated SCE formation after 3 or 44 h treatments, while VP-16, a cleavable...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199707000-00013

    authors: Hamatake M,Andoh T,Ishida R

    更新日期:1997-07-01 00:00:00

  • Isolation of two cellular lines resistant to ribonucleotide reductase inhibitors to investigate the inhibitory activity of 2,2'-bipyridyl-6-carbothioamide.

    abstract::The mechanism of action of a synthetic compound--2,2'-bipyridyl-6-carbothioamide--was investigated by developing tumor lines resistant to it (P388-R1.5 and P388-R4). P388-R4 is resistant to inhibitors of ribonucleotide reductase (RR) while no resistance was observed to antitumor drugs having other targets (except to b...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199012000-00009

    authors: Nocentini G,Federici F,Armellini R,Franchetti P,Barzi A

    更新日期:1990-12-01 00:00:00

  • Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells.

    abstract::Analog II (1,1-dichloro-cis-2,3-diarylcyclopropane), previously shown to be a pure antiestrogen in mice, was examined for potential antitumor activity on human breast cancer cells in culture. In this study, Analog II produced a dose-related antiproliferative effect on the growth of estrogen receptor (ER)-positive MCF-...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199711000-00008

    authors: Jain PT,Rajah TT,Pento JT

    更新日期:1997-11-01 00:00:00

  • An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.

    abstract:UNLABELLED:Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performa...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199708000-00002

    authors: Kudelka AP,Winn R,Edwards CL,Downey G,Greenberg H,Dakhil SR,Freedman RS,LoCoco S,Umbreit J,Delmore JE,Arbuck S,Loyer E,Gacrama P,Fueger R,Kavanagh JJ

    更新日期:1997-08-01 00:00:00